Abstract
Density notification laws require notifying women of dense breasts with dense breast prevalence varying by race/ethnicity. We evaluated whether differences in body mass index (BMI) account for differences in dense breasts prevalence by race/ethnicity.
Prevalence of dense breasts (heterogeneously or extremely dense) according to Breast Imaging Reporting and Data System and obesity (BMI > 30 kg/m2) were estimated from 2,667,207 mammography examinations among 866,033 women in the Breast Cancer Surveillance Consortium (BCSC) from January 2005 through April 2021. Prevalence ratios (PR) for dense breasts relative to overall prevalence by race/ethnicity were estimated by standardizing race/ethnicity prevalence in the BCSC to the 2020 U.S. population, and adjusting for age, menopausal status, and BMI using logistic regression.
Dense breasts were most prevalent among Asian women (66.0%) followed by non-Hispanic/Latina (NH) White (45.5%), Hispanic/Latina (45.3%), and NH Black (37.0%) women. Obesity was most prevalent in Black women (58.4%) followed by Hispanic/Latina (39.3%), NH White (30.6%), and Asian (8.5%) women. The adjusted prevalence of dense breasts was 19% higher [PR = 1.19; 95% confidence interval (CI), 1.19–1.20] in Asian women, 8% higher (PR = 1.08; 95% CI, 1.07–1.08) in Black women, the same in Hispanic/Latina women (PR = 1.00; 95% CI, 0.99–1.01), and 4% lower (PR = 0.96; 95% CI, 0.96–0.97) in NH White women relative to the overall prevalence.
Clinically important differences in breast density prevalence are present across racial/ethnic groups after accounting for age, menopausal status, and BMI.
If breast density is the sole criterion used to notify women of dense breasts and discuss supplemental screening it may result in implementing inequitable screening strategies across racial/ethnic groups.
Introduction
Having dense breasts (heterogeneously or extremely dense) is a strong, well-established risk factor that increases invasive (1, 2), interval (3–5), and advanced (6, 7) breast cancer risk, and reduces mammography sensitivity (8, 9). Breast density notification laws have been enacted in at least 38 states and a national density notification law will be enacted September 10, 2024 that will inform all women if their breasts are nondense or dense and that dense breasts can mask tumors and increase breast cancer risk (10). Dense breasts are common (11), and studies have shown that the distribution of breast density categories varies across racial and ethnic groups (12, 13). For example, Asian women are more likely to have dense breasts than non-Hispanic/Latina (NH) White women (1), and some studies show that Black and Hispanic/Latina women are less likely to have dense breasts than NH White women (14–17).
Body mass index (BMI) is inversely associated with breast density (11); accounting for BMI strengthens the association between breast density and breast cancer risk (18). Racial/ethnic differences in breast density may be confounded by BMI because obesity varies widely across groups with more than 50% of Black women being obese compared with less than 10% of Asian women (13, 19). In addition, being overweight/obese is a risk factor for breast cancer and women who are both overweight/obese and have dense breasts are at highest breast cancer risk (15, 18, 20).
Prior studies reporting breast density by race/ethnicity have been limited by small sample sizes, reporting results only for limited number of racial/ethnic groups, and reporting results for breast density and BMI separately, not jointly (14, 16, 21–31). Whether differences in BMI account for racial/ethnic differences in the prevalence of dense breasts is not well understood. We used the large, racially, ethnically, and geographically diverse Breast Cancer Surveillance Consortium (BCSC) cohort to estimate and compare prevalence of dense breasts by race/ethnicity adjusting for age, menopausal status, and BMI.
Materials and Methods
Study setting, data sources, and participants
This report follows STROBE reporting guidelines for cohort studies. Prospective data were collected at seven U.S.-based BCSC registries (www.bcsc-research.org): Carolina Mammography Registry, Kaiser Permanente Washington, Metro Chicago Breast Cancer Registry, New Hampshire Mammography Network, Sacramento Area Breast Imaging Registry, San Francisco Mammography Registry, and Vermont Breast Cancer Surveillance System. Registries collect individual-level characteristics and clinical information from community radiology facilities and link to state or regional cancer registries and pathology databases for complete capture of breast cancer diagnoses. We included all digital mammography and digital breast tomosynthesis screening examinations from 140 BCSC facilities performed from January 2005 to April 2021 among women ages 40 to 74 years without a personal history of breast cancer; nonmissing information on Breast Imaging Reporting and Data System (BI-RADS) breast density and BMI; and who self-identified as Hispanic/Latina (of any race) or NH Asian, Black, or White. We excluded women who self-identified as another race or as having multiple races. The final study population included 2,667,207 BI-RADS breast density measurements from 866,033 women interpreted.
BCSC registries and the Statistical Coordinating Center received Institutional Review Board (IRB) approval for active or passive consenting processes or a waiver of consent to enroll participants, link, and pool data, and perform analysis. Procedures were Health Insurance Portability and Accountability Act compliant, and a Federal Certificate of Confidentiality protects the identities of participants.
Measures, definitions, and outcomes
Age, height, weight, menopausal status, race, and ethnicity were collected from self-administered health history questionnaires or extracted from electronic health records at the time of each mammography examination. BMI was calculated as weight in kilograms divided by height in meters squared (kg/m2) and categorized as underweight (< 18.5), normal weight (18.5–24.9), overweight (25.0–29.9), obesity class I (30.0–34.4), and obesity class II/III (≥ 35.0; ref. 32). Postmenopausal status included women who reported periods that stopped naturally, had both ovaries removed, were age 60 years or older, or had no period for ≥ 365 days. Pre/perimenopausal status included women who reported continued menstrual periods, were not sure if periods had stopped, had their last menstrual period < 365 days ago, or used hormonal birth control. Women who could not be classified using these definitions were considered postmenopausal if age ≥ 52 years or pre/perimenopausal if age < 52 years.
Primary outcomes were a dichotomized density as dense (heterogeneously dense or extremely dense) versus nondense (almost entirely fatty or scattered fibroglandular densities) breasts, which is typically utilized for breast density reporting laws, and the four BI-RADS breast density categories recorded by the radiologist as part of clinical practice as almost entirely fatty, scattered fibroglandular densities, heterogeneously dense, or extremely dense (33).
Statistical analysis
We summarized the study cohort characteristics by race/ethnicity, inversely weighting frequencies by the total number of observations each woman contributed to the study, giving an effective sample size equal to the number of women. We plotted the age-standardized joint distribution of BI-RADS breast density and BMI by race/ethnicity, inversely weighing by the total number of observations each woman contributed. We used age-standardized pairwise Mantel–Haenszel (MH) and Cochran–Mantel–Haenszel (CMH) tests of significance to test if the distribution of breast density within BMI strata differed by race/ethnicity and to test if the joint distribution of breast density and BMI differed by race/ethnicity.
We used logistic regression to model the probability of having dense versus nondense breasts and polytomous logistic regression with a generalized-logit link to estimate the distribution of the four breast density categories to model the probabilities of having dense versus nondense breasts and the four breast density categories as a function of race/ethnicity, fitting three sequential models: unadjusted; adjusted for age (linear and quadratic) and menopausal status; and additionally adjusted for BMI (linear and quadratic). We used predictive margins to compute race/ethnicity-specific estimates of the density probabilities, standardizing to the overall cohort distribution for the adjustment variables (34). We estimated the race and ethnicity-specific distribution in the United States from the 2020 census (https://data.census.gov/cedsci/table?q=Race%20and%20Ethnicity&g=0100000US&tid=DECENNIALPL2020.P2) and used model-predicted probabilities for each density category and racial/ethnic group in the BCSC to calculate prevalence ratios (PR) of each breast density category for each racial/ethnic group relative to the estimated overall prevalence for the U.S. population; 95% confidence intervals (CI) were computed using 10,000 nonparametric bootstrap (35) iterations clustered at the woman level and selecting one random observation per woman, which showed good convergence for the mean PR estimates.
Statistical analyses were performed using SAS/STAT version 14.2, R version 4.1.2, and RStudio version 2021.9.1.372. Tests of statistical significance used a two-sided α of 0.05.
Data availability
Study protocol and statistical code are available on request (please contact [email protected] with specific queries). Dataset available after study aims of funded grants through 2027 are addressed and with appropriate approval from the BCSC Steering Committee. The data underlying this article will be shared on reasonable request to the corresponding author and BCSC with appropriate regulatory approvals.
Results
NH White women constituted 67.8% of the cohort, followed by Asian (12.8%), NH Black (11.8%), and Hispanic/Latina (7.5%) women (Table 1). Age distributions were generally similar across racial/ethnic groups, except a larger proportion of Hispanic/Latina women were 40–49 years old. Asian women had the largest prevalence of dense breasts (65.9%) followed by NH White (45.5%), Hispanic/Latina (45.2%), and NH Black (36.9%) women. Obesity was most prevalent in NH Black women (58.4%) followed by Hispanic/Latina (39.3%), NH White (30.6%), and Asian (8.5%) women.
. | NH Asian N = 111,209 . | NH Black N = 102,388 . | Hispanic/Latina N = 65,117 . | NH White N = 587,320 . |
---|---|---|---|---|
Age group (years) | % | % | % | % |
40–49 | 32.1 | 28.2 | 40.2 | 28.6 |
50–59 | 34.4 | 33.8 | 33.1 | 32.7 |
60–69 | 26.4 | 27.3 | 20.2 | 28.2 |
70–74 | 7.0 | 10.7 | 6.4 | 10.6 |
Menopausal status | ||||
Pre/perimenopausal | 40.6 | 38.5 | 48.2 | 36.6 |
Postmenopausal | 59.4 | 61.5 | 51.8 | 63.4 |
BI-RADS breast density | ||||
Almost entirely fatty | 4.2 | 12.4 | 10.7 | 11.3 |
Scattered fibroglandular densities | 29.9 | 50.7 | 44.1 | 43.2 |
Heterogeneously dense | 49.9 | 33.3 | 39.4 | 37.6 |
Extremely dense | 16.1 | 3.7 | 5.9 | 7.9 |
BMI (kg/m2) | ||||
Underweight (<18.5 kg) | 3.5 | 0.6 | 0.7 | 1.5 |
Normal (18.5–24.9 kg) | 61.9 | 13.5 | 25.6 | 39.3 |
Overweight (25.0–29.9 kg) | 26.1 | 27.5 | 34.4 | 28.7 |
Obese I (30.0–34.9 kg) | 6.5 | 26.1 | 22.8 | 16.6 |
Obese II/III (≥35.0 kg) | 2.0 | 32.3 | 16.5 | 14.0 |
BI-RADS breast density measures per woman | ||||
1 | 40.5 | 36.6 | 41.0 | 32.3 |
2 | 23.5 | 22.6 | 23.2 | 19.7 |
3 | 13.3 | 13.5 | 13.1 | 12.7 |
4 | 8.4 | 9.3 | 8.3 | 9.6 |
5 or more | 14.2 | 17.9 | 14.3 | 25.6 |
. | NH Asian N = 111,209 . | NH Black N = 102,388 . | Hispanic/Latina N = 65,117 . | NH White N = 587,320 . |
---|---|---|---|---|
Age group (years) | % | % | % | % |
40–49 | 32.1 | 28.2 | 40.2 | 28.6 |
50–59 | 34.4 | 33.8 | 33.1 | 32.7 |
60–69 | 26.4 | 27.3 | 20.2 | 28.2 |
70–74 | 7.0 | 10.7 | 6.4 | 10.6 |
Menopausal status | ||||
Pre/perimenopausal | 40.6 | 38.5 | 48.2 | 36.6 |
Postmenopausal | 59.4 | 61.5 | 51.8 | 63.4 |
BI-RADS breast density | ||||
Almost entirely fatty | 4.2 | 12.4 | 10.7 | 11.3 |
Scattered fibroglandular densities | 29.9 | 50.7 | 44.1 | 43.2 |
Heterogeneously dense | 49.9 | 33.3 | 39.4 | 37.6 |
Extremely dense | 16.1 | 3.7 | 5.9 | 7.9 |
BMI (kg/m2) | ||||
Underweight (<18.5 kg) | 3.5 | 0.6 | 0.7 | 1.5 |
Normal (18.5–24.9 kg) | 61.9 | 13.5 | 25.6 | 39.3 |
Overweight (25.0–29.9 kg) | 26.1 | 27.5 | 34.4 | 28.7 |
Obese I (30.0–34.9 kg) | 6.5 | 26.1 | 22.8 | 16.6 |
Obese II/III (≥35.0 kg) | 2.0 | 32.3 | 16.5 | 14.0 |
BI-RADS breast density measures per woman | ||||
1 | 40.5 | 36.6 | 41.0 | 32.3 |
2 | 23.5 | 22.6 | 23.2 | 19.7 |
3 | 13.3 | 13.5 | 13.1 | 12.7 |
4 | 8.4 | 9.3 | 8.3 | 9.6 |
5 or more | 14.2 | 17.9 | 14.3 | 25.6 |
Abbreviations: BMI, body mass index; kg, kilograms; m, meters; NH, nonHispanic/Latina.
aFrequencies are inversely weighted by the number of observations per woman and rounded.
The age-adjusted distribution of breast density within each BMI category (Fig. 1) and the joint distribution of breast density and BMI were significantly different across racial/ethnic groups (Supplementary Fig. S1; all P < 0.0001). Asian women had the highest prevalence of dense breasts within each BMI category. NH Black and Hispanic/Latina women had lower prevalence of dense breasts within the underweight and normal BMI categories compared with White women, but higher prevalence within overweight and obese I/II/III categories. There was an inverse relationship between BMI and breast density for all racial/ethnic groups.
Results were largely unchanged with partial adjustment for age and menopausal status, with larger changes after additional adjustment for BMI (Table 2). Relative to the overall population, Asian women had a higher prevalence of dense breasts in both unadjusted and adjusted models. The fully adjusted prevalence of dense breasts was 19% higher (PR = 1.19; 95% CI, 1.19–1.20) in Asian women, 8% higher (PR = 1.08; 95% CI, 1.07–1.08) in NH Black women, (PR = 1.00; 95% CI, 0.99–1.01) the same in Hispanic/Latina women, and 4% lower (PR = 0.96; 95% CI, 0.96–0.97) in White women relative to the overall prevalence.
Model . | Race/ethnicity . | Nondense PR . | Dense PR . |
---|---|---|---|
Unadjusteda | NH Asian | 0.62 (0.62–0.63) | 1.45 (1.44–1.46) |
NH Black | 1.16 (1.15–1.16) | 0.81 (0.81–0.82) | |
Hispanic/Latina | 1.00 (1.00–1.01) | 0.99 (0.99–1.00) | |
NH White | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) | |
Partially adjustedb | NH Asian | 0.62 (0.62–0.63) | 1.48 (1.47–1.49) |
NH Black | 1.15 (1.15–1.16) | 0.82 (0.81–0.82) | |
Hispanic/Latina | 1.06 (1.05–1.07) | 0.93 (0.92–0.93) | |
NH White | 0.98 (0.98–0.99) | 1.02 (1.02–1.02) | |
Fully adjustedc | NH Asian | 0.84 (0.83–0.85) | 1.19 (1.19–1.20) |
NH Black | 0.93 (0.93–0.94) | 1.08 (1.07–1.08) | |
Hispanic/Latina | 1.00 (0.99–1.01) | 1.00 (0.99–1.01) | |
NH White | 1.03 (1.03–1.03) | 0.96 (0.96–0.97) |
Model . | Race/ethnicity . | Nondense PR . | Dense PR . |
---|---|---|---|
Unadjusteda | NH Asian | 0.62 (0.62–0.63) | 1.45 (1.44–1.46) |
NH Black | 1.16 (1.15–1.16) | 0.81 (0.81–0.82) | |
Hispanic/Latina | 1.00 (1.00–1.01) | 0.99 (0.99–1.00) | |
NH White | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) | |
Partially adjustedb | NH Asian | 0.62 (0.62–0.63) | 1.48 (1.47–1.49) |
NH Black | 1.15 (1.15–1.16) | 0.82 (0.81–0.82) | |
Hispanic/Latina | 1.06 (1.05–1.07) | 0.93 (0.92–0.93) | |
NH White | 0.98 (0.98–0.99) | 1.02 (1.02–1.02) | |
Fully adjustedc | NH Asian | 0.84 (0.83–0.85) | 1.19 (1.19–1.20) |
NH Black | 0.93 (0.93–0.94) | 1.08 (1.07–1.08) | |
Hispanic/Latina | 1.00 (0.99–1.01) | 1.00 (0.99–1.01) | |
NH White | 1.03 (1.03–1.03) | 0.96 (0.96–0.97) |
Abbreviations: BI-RADS, Breast Imaging Reporting and Data System; CIs, confidence intervals; NH, non-Hispanic/Latina; PR, prevalence ratio = prevalence of racial/ethnic and density group relative to overall Breast Cancer Surveillance Consortium (BCSC) study population standardized to the U.S. population.
aUnadjusted race/ethnicity.
bAdditionally adjusted for age (linear and quadratic) and menopausal status.
cAdditionally adjusted for body mass index (linear and quadratic).
When examining results by the four density categories, unadjusted PRs for heterogeneously dense (PR = 1.31; 95% CI, 1.30–1.32) and extremely dense (PR = 2.17; 95% CI, 2.14–2.20) breasts in Asian women increased minimally to PR = 1.35 (95% CI, 1.34–1.35) and PR = 2.25 (95% CI, 2.22–2.29) after adjustment for age and menopause, but decreased substantially to PR = 1.16 (95% CI, 1.15–1.16) and PR = 1.48 (95% CI, 1.45–1.50) after additional adjustment for BMI (Fig. 2; Supplementary Table S1). NH Black women had lower unadjusted prevalence of heterogeneously dense (PR = 0.87; 95% CI, 0.87–0.88) and extremely dense (PR = 0.50; 95% CI, 0.48–0.51) breasts than the overall population, but following full adjustment for age, menopausal status, and BMI, they had higher prevalence of heterogeneously dense (PR = 1.08; 95% CI, 1.08–1.09) and extremely dense breasts (PR = 1.02; 95% CI, 0.99–1.05) than the overall population (Fig. 2; Supplementary Table S1). Hispanic/Latina women had a similar prevalence of dense breasts as the overall population in both unadjusted and adjusted models, but their lower prevalence of extremely dense breasts attenuated somewhat from unadjusted (PR = 0.79; 95% CI, 0.77–0.81) to fully adjusted (PR = 0.89; 95% CI, 0.86–0.91) models. NH White women were significantly more likely to have almost entirely fatty and significantly less likely to have heterogeneously or extremely dense breasts after adjustment for age, menopausal status, and BMI, though absolute differences were small.
Discussion
Among more than 2.6 million breast density measurements from 140 U.S.-based radiology facilities in the BCSC, we found clinically important differences in the prevalence of dense breasts across racial/ethnic groups that remained after adjusting for age, menopausal status, and BMI. Given BMI and breast density are both risk factors for breast cancer (13, 36) and the strength of their association with breast cancer varies by racial/ethnic groups (1), considering these prevalence differences may be important for estimating breast cancer risk in racial/ethnic groups and reporting breast density results to women.
The goal of breast density notification laws is to identify women at increased risk of breast cancer and masked tumors that may benefit from supplemental imaging. State laws do not consider other breast cancer risk factors, such as BMI, and the FDA Mammography Quality and Standards Act Final Rule has proposed to only report if women have dense or nondense breasts (10). Some have suggested that under current state notification laws, the use of BI-RADS breast density alone may result in suboptimal risk stratification and recommendations for supplemental imaging (5, 37–39, 40). Our study suggests that Asian women are most likely to have dense breasts with associated density notification letters suggesting consideration of supplemental imaging, whereas Black women are less likely to have dense breasts which do not trigger letters suggesting consideration of supplemental imaging. Specifically, Asian women are most likely to be notified of dense breasts irrespective of adjustment for BMI, whereas Black women are less likely to be notified of dense breasts if density is not adjusted for BMI. Studies indicate disparities already exist such that non-Hispanic White women are more likely to have supplemental imaging for dense breasts than non-Hispanic Black or Asian women which may lead to disparities in cancer outcomes (39, 41). In addition, advanced cancer rates after mammography are higher in Black women (7) and interval rates are lower in Asian women (42). Reporting breast cancer risk that incorporates breast density and BMI would better identify women at highest risk of a missed or advanced cancer for discussion of supplemental imaging rather than using breast density alone as the sole criterion (5, 7, 38) with the result of potentially more equitable receipt of supplemental imaging.
BI-RADS breast density is a qualitative measure of the relative proportion of fibroglandular and fat tissue on mammograms that is inversely associated with BMI. Dense volume is a quantitative measure of the volume of fibroglandular tissue that can be measured with commercial software and is minimally influenced by BMI or increased among overweight and obese women (18, 27, 43). Volpara and Quantra are FDA-approved commercial software used in clinical practice to assess volumetric breast density. Although Asian women have the highest prevalence of BI-RADS dense breasts, they have the lowest dense volume (43). Thus, many Asian women, in whom a large proportion have dense BI-RADS breast density and normal BMI, may be inappropriately notified, and recommended for supplemental imaging recommendations under current notification laws on the basis of BI-RADS breast density alone. Dense volume is a strong predictor of interval and advanced cancers, and, if used for density notification, would more accurately identify women at risk for a missed cancer than BI-RADS breast density unadjusted for BMI (44, 45).
Five studies have examined BI-RADS breast density by race/ethnicity considering age, menopausal status, and BMI. McCarthy and colleagues reported that Black women had higher breast density than White women across all quantitative measures of breast density and no difference in the qualitative BI-RADS density distribution by race (27). Moore and colleagues compared Black and White women and found that Black women had a higher odds of extremely dense breasts than White women (46). Oppong and colleagues compared BI-RADS breast density in non-Hispanic/Latina White, Black, and Hispanic/Latina women and found Hispanic/Latina women have the highest density followed by Black and NH White women (28). One study examined Asian, Black, non-Hispanic White, and Hispanic/Latina women and compared dense breasts to almost entirely fatty breasts and found Asian and Black women have higher odds of dense breasts than Hispanic/Latina and NH White women, which have similar odds of dense breasts (12). A recent study observed the lowest prevalence of extremely dense breasts among American Indian and Alaska native women and the greatest prevalence of extremely dense breasts among Chinese women (47). Our results extend the literature by assessing BI-RADS breast density in the BCSC cohort, a large representative sample of U.S. women, and report that the adjusted prevalence of dense breasts is highest in Asian and Black women compared with Hispanic and White women after adjusting for BMI. These results are consistent with a study that measured the same four racial/ethnic groups but assessed odds of extremely dense breasts rather than prevalence of the four density categories (12).
Our study strengths include the large, geographically, and racially/ethnically diverse BCSC cohort, which is broadly representative of the U.S. population and has larger sample sizes than many other studies for the four largest United States racial and ethnic groups. Our analysis included both digital mammography and digital breast tomosynthesis, which reflect recent clinical practice. We have previously reported that BI-RADS breast density categories were similar on digital breast tomosynthesis exams compared with digital mammography exams (48). We also have demonstrated that density agreement on digital breast tomosynthesis versus digital mammography is high on the basis of women with both examinations less than 36 months apart (49).
Our study has limitations. Even with a very large study cohort and multiple observations per woman, some estimated CIs were wide due to small sample sizes for NH Black and Hispanic/Latina women in the underweight category or for Asian women in the obese I/II/III categories, but sample sizes were still larger than many other studies. We were unable to evaluate quantitative measures of breast density; however, BI-RADS breast density is the most commonly collected density measure in clinical practice in the United States, triggers density notification laws, and is used in several major breast cancer risk prediction models (36, 50, 51). We were not able to analyze other measures of adiposity, such as central adiposity, waist-to-hip ratios, or visceral versus subcutaneous fat distribution, and BMI was primarily self-reported, but there is good overall agreement between self-reported and measured height, weight, and BMI (52). Also, BMI measures in the BCSC cohort have associations with breast cancer consistent with the literature (38), suggesting self-reported height and weight in the BCSC reflect height and weight measures in published studies. We did not consider other factors that are correlated with breast density, such as a family history of breast cancer, but this association is weaker compared with age and BMI, reduced by controlling for age and BMI (11), and does not vary by race/ethnicity (53). However, caution should be used in extrapolating the results of this study to populations that vary markedly in such characteristics.
Clinically important differences in the prevalence of dense breasts across racial/ethnic groups remain after adjusting for BMI. The probability of dense breasts assessed by BI-RADS compared with the overall U.S. population for Asian women was attenuated but remained high following adjustment for BMI. The probability of dense breasts in NH Black women increased after adjustment for BMI. Hispanic/Latina women had significantly lower probability of extremely dense breasts compared with the general population with and without adjustment for BMI. Current density notification laws that only require notification of breast density may intensify racial/ethnic disparities when assessing eligibility for supplemental imaging if they do not consider the joint effects of BMI and breast density on risk of a missed or advanced cancer. Differences in the distribution of breast density by race/ethnicity following adjustment for BMI has important implications for equity in breast density notification, access to supplemental imaging, and estimating population breast cancer risk. Directly calculating risk of mammography failure such as advanced breast cancer risk (7) that incorporates race/ethnicity, breast density, and BMI is warranted and could mitigate potential disparities in recommending supplemental imaging.
Authors' Disclosures
K. Kerlikowske reports grants from NCI and grants from PCORI during the conduct of the study. B.L. Sprague reports grants from NIH, grants from PCORI, and grants from Lake Champlain Cancer Research Organization during the conduct of the study; grants from American College of Radiology outside the submitted work. J.A. Tice reports grants from NCI during the conduct of the study; grants from NCI and grants from PCORI outside the submitted work. E.J. Aiello Bowles reports grants from National Cancer Institute during the conduct of the study. D.L. Miglioretti reports grants from NCI and grants from PCORI during the conduct of the study. No disclosures were reported by the other authors.
Disclaimer
The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute, its Board of Governors or Methodology Committee, the NCI, or the NIH.
Authors' Contributions
K. Kerlikowske: Conceptualization, resources, data curation, funding acquisition, investigation, writing–original draft, writing–review, and editing. M.C.S. Bissell: Conceptualization, data curation, formal analysis, investigation, methodology, writing–original draft, writing–review, and editing. B.L. Sprague: Conceptualization, resources, data curation, funding acquisition, investigation, methodology, writing–review, and editing. J.A. Tice: Conceptualization, investigation, writing–review, and editing. K.Y. Tossas: Investigation, writing–review, and editing. E.J.A. Bowles: Resources, data curation, funding acquisition, investigation, writing–review, and editing. T.-Q.H. Ho: Investigation, writing–review, and editing. T.H.M. Keegan: Conceptualization, investigation, methodology, writing–review, and editing. D.L. Miglioretti: Conceptualization, resources, data curation, formal analysis, supervision, funding acquisition, investigation, methodology, writing–original draft, writing–review, and editing.
Acknowledgments
This work was supported with funding from the NCI (P01CA154292) and the NIH Office of Research on Women's Health (3 P01CA154292 – 07S1) which supports effort for K. Kerlikowske, B.L. Sprague, J.A. Tice, D.L. Miglioretti, and Erin Bowles (P01CA154292) and M.C. Bissell (3 P01CA154292 – 07S1). Data collection for this research was additionally supported by the Breast Cancer Surveillance Consortium with funding from the NCI (P01CA154292; Kerlikowske, Sprague, Bowles, and Miglioretti; U54CA163303; Sprague, the Patient-Centered Outcomes Research Institute Program Award; PCS-1504–30370), the Agency for Healthcare Research and Quality (R01 HS018366–01A1; Dr. Garth Rauscher) and the University of Vermont Cancer Center with funds generously awarded by the Lake Champlain Cancer Research Organization (grant no. 032800). The collection of SABIR data was supported by the UC Davis Comprehensive Cancer Center, the Placer County Breast Cancer Foundation, and the UC Davis Clinical and Translational Science Center. Cancer and vital status data collection was supported by several state public health departments and cancer registries (http://www.bcsc-research.org/work/acknowledgement.html). B.L. Sprague's effort was also supported by the National Institute of General Medical Sciences (P20GM103644) and the National Cancer Institute (R01CA248068). E. Bowles’ time was funded by the NCI (R50CA211115). The authors thank Yang Vang from the University of California Davis Department of Public Health Sciences who provided data management but did not receive additional compensation besides their regular salary. We thank the participating individuals, mammography facilities, and radiologists for the data they have provided for this study. Information about the BCSC may be found at http://www.bcsc-research.org/.
The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (http://cebp.aacrjournals.org/).